Moderna Inc. stopped its efforts to develop mRNA-1647 as a vaccine for preventing congenital cytomegalovirus infection, the most common infectious cause of birth defects in the U.S. The pivotal and placebo-controlled phase III CMVictory study of mRNA-1647 missed the primary efficacy endpoint, which was preventing the infection in seronegative females ages 16 to 40. Read More
Ipsen SA is expanding its cancer portfolio with the €1 billion (US$1.16 billion) acquisition of immuno-oncology specialist Imcheck SAS, and will pay €350 million up front with the balance to come in regulatory and sales-based milestones for the lead program ICT-01. Read More
Ventyx Biosciences Inc. rolled out positive results from the phase II study with oral, once-daily VTX-3232 in patients with obesity and cardiovascular (CV) risk factors. Read More
Ena Respiratory Pty Ltd. raised an AU$34 million (US$22.4 million) series B round to advance INNA-051, its nasal spray for symptomatic viral respiratory infections, to phase II trials. New investors in the Melbourne-headquartered company include the Gates Foundation and Flu Lab. Existing investors Brandon Capital, Uniseed and Stoic Venture Capital also participated in the round. Read More
Stem cells are a promising therapeutic modality to fight aging and age-related disease, speakers at the Bio-Plus Interphex Korea 2025 said. Progress in cell-based longevity medicine is being made, they added, although safety, ethical and regulatory issues are ongoing challenges. Read More
A technology that combines transcriptomic data and AI enables a novel approach to drug discovery based on the state of cells, how they behave and which genes they express. The Drugreflector model, developed by scientists at Cellarity Inc., learns from gene expression profiles and predicts which compounds could induce beneficial changes in that cellular state to develop a treatment. Read More
From Dolly the sheep to mRNA vaccines, BioWorld has been reporting every breakthrough and challenge along the way. Our commitment to accurate, contextualized journalism has helped readers navigate this fast-evolving industry for 35 years. Join us as we celebrate the milestones that shaped biopharma and medtech, then and now. Read More
Clinical updates, including data readouts and publications: ACM Biolabs, Alector, Arcturus, Astellas, Dynavax, Iaso, Nanoscope, Novartis, OS Therapies, Perspective, Puretech, Sanofi, Terns. Read More
Biopharma happenings, including deals and partnerships, and other news in brief: AAX, Biossil, Daiichi Sankyo, Forlong, Galera, Henlius, Kyowa Kirin. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Adarx, Amgen, Astellas, Astrazeneca, Boehringer Ingelheim, Electra. Read More
